

Odkazy

Úvod

1. Epstein B. *A Cellarful of Noise*. Pocket Books, New York, 1967, 1998.

1. kapitola Zlepšete paměť a povzbudte intelekt

1. Albert M. S., DeKosky S. T., Dickson D. et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup. *Alzheimers and Dementia*. 2011; 7: 270–279.
2. de Jager C. A., Oulhaj A., Jacoby R., Refsum H., Smith A. D. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: A randomized controlled trial [online]. *International Journal of Geriatric Psychiatry*. 21. 7. 2011; doi: 10.1002/gps.2758.
3. Jean L., Bergeron M. E., Thivierge S., Simard M. Cognitive intervention programs for individuals with mild cognitive impairment: Systematic review of the literature. *American Journal of Geriatric Psychiatry*. 2010; 18: 281–296.
4. McKhann G. M., Knopman D. S., Chertkow H. et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging and the Alzheimer's Association workgroup. *Alzheimers and Dementia*. 2011; 7: 263–269.
5. Farrer L. A., Cupples L. A., Haines J. L. et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease: A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *JAMA*. 1997; 278: 1349–1356.
6. Graff-Radford N. R., Green R. C., Go R. C. et al. Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. *Archives of Neurology*. 2002; 59: 594–600.
7. Buchman A. S., Leurgans S. E., Nag S., Bennett D. A., Schneider J. A. Cerebrovascular disease pathology and parkinsonian signs in old age. *Stroke*. 2011; 42: 3183–3189.

2. kapitola Strava jako ochrana před toxickými kovy

1. Lovell M. A., Robertson J. D., Teesdale W. J., Campbell J. L., Markesbery W. R. Copper, iron and zinc in Alzheimer's disease senile plaques. *Journal of the Neurological Sciences*. 1998; 158: 47–52.

2. Stankiewicz J. M., Brass S. D. Role of iron in neurotoxicity: A cause for concern in the elderly? *Current Opinion Clinical Nutrition Metab Care*. 2009; 12: 22–29.
3. Salustri C., Barbati G., Ghidoni R. et al. Is cognitive function linked to serum free copper levels?: A cohort study in a normal population. *Clinical Neurophysiology*. 2010; 121: 502–507.
4. Lam P. K., Kritz-Silverstein D., Barrett-Connor E. et al. Plasma trace elements and cognitive function in older men and women: The Rancho Bernardo study. *Journal of Nutrition*. 2008; 12: 22–27.
5. Morris M. C., Evans D. A., Tangney C. C. et al. Dietary copper and high saturated and trans fat intakes associated with cognitive decline. *Archives of Neurology*. 2006; 63: 1085–88.
6. Brewer G. J. The risks of copper toxicity contributing to cognitive decline in the aging population and to Alzheimer's disease. *Journal of the American College of Nutrition*. 2009; 28: 238–242.
7. Schiepers O. J., van Boxtel M. P., de Groot R. H. et al. Serum iron parameters, HFE C282Y genotype, and cognitive performance in older adults: Results from the FACIT study. *Journals of Gerontology Series A: Biological Sciences and Medical Sciences*. 2010; 65: 1312–1321.
8. Shah R. C., Wilson R. S., Tang Y., Dong X., Murray A., Bennett D. A. Relation of hemoglobin to level of cognitive function in older persons. *Neuroepidemiology*. 2009; 32: 40–46.
9. Shah R. C., Buchman A. S., Wilson R. S., Leurgans S. E., Bennett D. A. Hemoglobin level in older persons and incident Alzheimer disease: Prospective cohort analysis. *Neurology*. 2011; 77: 219–26.
10. Huang X., Cuajungco M. P., Atwood C. S., Moir R. D., Tanzi R. E., Bush AI. Alzheimer's disease, beta-amyloid protein and zinc. *Journal of Nutrition*. 2000; 130: 1488S–1492S.
11. Watt N. T., Whitehouse I. J., Hooper N. M. The role of zinc in Alzheimer's disease. *International Journal of Alzheimers Disease*. 2011; 9710–9721.
12. Smith M. A., Harris P. L. R., Sayre L. M., Perry G. Iron accumulation in Alzheimer's disease is a source of redox-generated free radicals. *Proc Nat Acad Sciences of the United States of America*. 1997; 94: 9866–9868.
13. Environmental Protection Agency. *Basic information about copper in drinking water*. [online] [vid. 3. 10. 2011] Dostupné na: <http://water.epa.gov/drink/contaminants/basicinformation/copper.cfm>.
14. Hunt J. R. Bioavailability of iron, zinc, and other trace minerals from vegetarian diets. *AJCN*. 2003; 78 (dodatek): 633S–639S.

15. Hunt J. R., Vanderpool R. A. Apparent copper absorption from a vegetarian diet. *AJCN*. 2001; 74: 803–7.
16. Kadrabová J., Mađarič A., Kovaciková Z., Ginter E. Selenium status, plasma zinc, copper, and magnesium in vegetarians. *Biological Trace Element Research*. 1995; 50: 13–24.
17. Crapper D. R., Kishnan S. S., Dalton A. J. Brain aluminum distribution in Alzheimer's disease and experimental neurofibrillary degeneration. *Science*. 1973; 180: 511–13.
18. Crapper D. R., Krishnan S. S., Quittkat S. Aluminium, neurofibrillary degeneration and Alzheimer's disease. *Brain*. 1976; 99: 67–80.
19. Miu A. C., Benga O. Aluminum and Alzheimer's disease: A new look. *Journal of Alzheimer's Disease*. 2006; 10: 179–201.
20. Bolognin S., Messori L., Drago D., Gabbiani C., Cendron L., Zatta P. Aluminum, copper, iron and zinc differentially alter amyloid-A β (1-42) aggregation and toxicity. *International Journal of Biochemistry and Cell Biology*. 2011; 43: 877–85.
21. Martyn C. N., Osmond C., Edwardson J. A., Barker D. J. P, Harris E. C., Lacey R. F. Geographical relation between Alzheimer's disease and aluminium in drinking water. *Lancet*. 1989; 333: 61–62.
22. Rondeau V., Jacqmin-Gadda H., Commenges D., Helmer C., Dartigues J.-F. Aluminum and silica in drinking water and the risk of Alzheimer's disease or cognitive decline: Findings from 15-year follow-up of the PAQUID cohort. *American Journal of Epidemiology*. 2009;169:489–96.
23. Frecker M. F. Dementia in Newfoundland: Identification of a geographical isolate? *Journal of Epidemiology and Community Health*. 1991; 45: 307–311.
24. Gauthier E., Fortier I., Courchesne F., Pepin P., Mortimer J., Gauvreau D. Aluminum forms in drinking water and risk of Alzheimer's disease. *Environmental Research* 2000; 84: 234–246.
25. Forster D. P., Newens A. J., Kay D. W., Edwardson J. A. Risk factors in clinically diagnosed presenile dementia of the Alzheimer type: A case-control study in northern England. *Journal of Epidemiology and Community Health*. 1995; 49: 253–258.
26. Taylor G. A., Newens A. J., Edwardson J. A., Kay D. W. K., Forster D. P. Alzheimer's disease and the relationship between silicon and aluminum in water supplies in northern England. *Journal of Epidemiology and Community Health*. 1995; 49: 323–328.
27. Forbes W. F., McLachlan D.R. Further thoughts on the aluminum-Alzheimer's disease link. *Journal of Epidemiology and Community Health*. 1996; 50: 401–403.

28. Doll R. Review: Alzheimer's disease and environmental aluminum. *Age Ageing*. 1993; 22: 138–153.
29. Alzheimer's Association. *Alzheimer's Myths* [online] [vid. 16. 9. 2011] Dostupné na: http://www.alz.org/alzheimers_disease_myths_about_alzheimers.asp.
30. Kawahara M., Kato-Negishi M. Link between aluminum and the pathogenesis of Alzheimer's disease: The integration of the aluminum and amyloid cascade hypotheses. *International Journal of Alzheimer's Disease*. 2011; 276393.
31. Duggan J. M., Dickeson J. E., Tynan P. F., Houghton A., Flynn J. E. Aluminum beverage cans as a dietary source of aluminium. *Medical Journal of Australia*. 1992; 156: 604–605.
32. Saiyed S. M., Yokel R. A. Aluminium content of some foods and food products in the USA, with aluminium food additives. *Food Additives and Contaminants*. 2005; 22: 234–244.
33. Mutter J., Naumann J., Schneider R., Walach H. Mercury and Alzheimer's disease. *Fortschr Neurol Psychiatr*. 2007; 75: 528–38.
34. Bates M. N. Mercury amalgam dental fillings: An epidemiologic assessment. *International Journal of Hygiene and Environmental Health*. 2006; 209: 309–316.
35. Saxe S. R., Wekstein M. W., Kryscio R. J. et al. Alzheimer's disease, dental amalgam and mercury. *Journal of the American Dental Association*. 1999; 130: 191–99.

3. kapitola Strava jako ochrana před škodlivými tuky a cholesterolem

1. Giem P., Beeson W. L., Fraser G. E. The incidence of dementia and intake of animal products: Preliminary findings from the Adventist Health Study. *Neuroepidemiology* 1993; 12: 28–36.
2. National Cancer Institute. *Top food sources of saturated fat among US population, 2005–2006 NHANES* [online] [vid. 2. 10. 2011]. Dostupné na: http://riskfactor.cancer.gov/diet/foodsources/sat_fat/sf.html.
3. Morris M. C., Evans E. A., Bienias J. L. et al. Dietary fats and the risk of incident Alzheimer's disease. *Archives of Neurology*. 2003; 60: 194–200.
4. Luchsinger J. A., Tang M. X., Shea S., Mayeux R. Caloric intake and the risk of Alzheimer disease. *Archives of Neurology*. 2002; 59: 1258–63.
5. Scarmeas N., Luchsinger J. A., Schupf N. et al. Physical activity, diet, and risk of Alzheimer disease. *JAMA*. 2009; 302: 627–37.
6. Laitinen M. H., Ngandu T., Rovio S. et al. Fat intake at midlife and risk of dementia and Alzheimer's disease: A population-based study. *Dementia and Geriatric Cognitive Disorders*. 2006; 22: 99–107.
7. Engelhart M. J., Geerlings M. I., Ruitenberg A. Diet and risk of dementia: Does fat matter? The Rotterdam Study. *Neurology*. 2002; 59: 1915–1921.

8. Solomon A., Kivipelto M., Wolozin B., Zhou J., Whitmer R. A. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. *Dementia and Geriatric Cognitive Disorders*. 2009; 28: 75–80.

9. Puglielli L., Tanzi R. E., Kovacs D. M. Alzheimer's disease: The cholesterol connection. *Nature Neuroscience*. 2003; 6: 345–351.

10. Anoop S., Anoop M., Meena K., Luthra K. Apolipoprotein E polymorphism in cerebrovascular & coronary heart diseases. *Indian Journal of Medical Research*. 2010; 132: 363–378.

11. Petot G. J., Traore F., Debanne S. M., Lerner A. J., Smyth K. A., Friedland R. P. Interactions of apolipoprotein E genotype and dietary fat intake of healthy older persons during mid-adult life. *Metabolism*. 2003; 52: 279–281.

12. McGuinness B., Craig D., Bullock R., Passmore P. Statins for the prevention of dementia. *Cochrane Database of Systematic Reviews*. 2009; 15: CD003160.

13. Heude B., Ducimetiere P., Berre C., EVA Study. Cognitive decline and fatty acid composition of erythrocyte membranes—The EVA Study. *AJCN*. 2003; 77: 803–808.

14. Conquer J. A., Tierney M. C., Zecevic J., Bettger W. J., Fisher R. H. Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. *Lipids*. 2000; 35: 1305–1312.

15. Kroger E., Verreault R., Carmichael P. H. et al. Omega-3 fatty acids and risk of dementia: The Canadian Study of Health and Aging. *AJCN*. 2009; 90: 184–192.

16. Davis B. C., Kris-Etherton P. M. Achieving optimal essential fatty acid status in vegetarians: Current knowledge and practical implications. *AJCN*. 2003; 78 (suppl): 640S–646S.

17. Dangour A. D., Allen E., Elbourne D. et al. Effect of 2-y n-3 long-chain polyunsaturated fatty acid supplementation on cognitive function in older people: A randomized, double-blind, controlled trial. *AJCN*. 2010; 91: 1725–1732.

18. Van de Rest O., Geleijnse J. M., Kok F. J. et al. Effect of fish oil on cognitive performance in older subjects: A randomized, controlled trial. *Neurology*. 2008; 71: 430–438.

19. Quinn J. F., Rama R., Thomas R. G. et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial. *JAMA*. 2010; 304: 1903–1911.

20. Morris M. C., Evans D. A., Tangney C. C., Bienias J. L., Wilson R. S. Fish consumption and cognitive decline with age in a large community study. *Archives of Neurology*. 2005; 62: 1849–1853.

21. Tangney C. C., Kwasny M. J., Li H., Wilson R. S., Evans D. A., Morris M. C. Adherence to a Mediterranean-type dietary pattern and cognitive decline in a community population. *AJCN*. 2011; 93: 601–607.
22. Tonstad S., Butler T., Yan R., Fraser G. E. Type of vegetarian diet, body weight and prevalence of type 2 diabetes. *Diabetes Care*. 2009; 32: 791–796.
23. Marckmann P., Gronbaek M. Fish consumption and coronary heart disease mortality: A systematic review of prospective cohort studies. *European Journal of Clinical Nutrition*. 1999; 53: 585–590.
24. Feart C., Samieri C., Rondeau V. et al. Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. *JAMA*. 2009; 302: 638–648.
25. Barnard N. D., Scialli A. R., Turner-McGrievy G., Lanou A. J., Glass J. The effects of a low-fat, plant-based dietary intervention on body weight, metabolism, and insulin sensitivity. *American Journal of Medicine*. 2005; 118: 991–997.
26. Berkow S., Barnard N. D. Vegetarian diets and weight status. *Nutrition Reviews*. 2006; 64: 175–188.
27. Turner-McGrievy G. M., Barnard N. D., Scialli A. R. A two-year randomized weight loss trial comparing a vegan diet to a more moderate low-fat diet. *Obesity*. 2007; 15: 2276–2281.
28. Gustafson D. An 18-year follow-up of overweight and risk of Alzheimer's disease. *Archives of Internal Medicine*. 2003; 163: 1524–1528.
29. Berkow S., Barnard N. D. Blood pressure regulation and vegetarian diets. *Nutrition Reviews*. 2005; 63: 1–8.

4. kapitola Strava vytvářející vitaminový štít

1. Devore E. E., Grodstein F., van Rooij F. J., Hofman A., Stampfer M. J., Witteman J. C., Breteler M. M. Dietary antioxidants and long-term risk of dementia. *Archives of Neurology*. 2010; 67: 819–825.
2. Morris M. C., Evans D. A., Bienias J. L., Tangney C. C., Bennett D. A., Aggarwal N., Wilson R. S., Scherr P. A. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. *JAMA*. 2002; 287: 3230–3237.
3. Morris M. C., Evans D. A., Tangney C. C. et al. Relation of the tocopherol forms to incident Alzheimer disease and cognitive change. *AJCN*. 2005; 81: 508–514.
4. Laurin D., Foley D. J., Masaki K. H., White L. R., Launer L. J. Vitamin E and C supplements and risk of dementia. *JAMA*. 2002; 288: 2266–2268.
5. Sano M., Ernesto C., Thomas R. G. et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. *New England Journal of Medicine*. 1997; 336: 1216–1222.

6. Thomas R. G., Gebhardt S. E. *Nuts and seeds as sources of alpha and gamma tocopherols* [online]. USDA-ARS Nutrient Data Laboratory, Beltsville, MD. [vid. 17. 6. 2011]. Dostupné na: http://www.ars.usda.gov/SP2UserFiles/Place/12354500/Articles/AICR06_NutSeed.pdf.
7. Brewer G. J. The risks of copper toxicity contributing to cognitive decline in the aging population and to Alzheimer's disease. *Journal of the American College Nutrition*. 2009; 28: 238–242.
8. Durga J., van Boxtel M. P., Schouten E. G. et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: A randomised, double blind, controlled trial. *Lancet*. 2007a; 369: 208–216.
9. de Jager C. A., Oulhaj A., Jacoby R., Refsum H., Smith A. D. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: A randomized controlled trial. *International Journal of Geriatric Psychiatry*. 2011; Jul 21. doi: 10.1002/gps.2758.
10. Durga J., Verhoef P., Anteunis L. J., Schouten E., Kok F. J. Effects of folic acid supplementation on hearing in older adults: A randomized, controlled trial. *Annals of Internal Medicine*. 2007; 146: 1–9.
11. Ravaglia G., Forti P., Maioli F., Martelli M., Servadei L., Brunetti N., Porcellini E., Licastro F. Homocysteine and folate as risk factors for dementia and Alzheimer disease. *AJCN*. 2005; 82: 636–643.
12. Tucker K. L., Qiao N., Scott T., Rosenberg I., Spiro A. 3rd. High homocysteine and low B vitamins predict cognitive decline in aging men: The Veterans Affairs Normative Aging Study. *AJCN*. 2005; 82: 627–635.
13. Aisen P. S., Schneider L. S., Sano M. et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer's disease: A randomized controlled trial. *JAMA*. 2008; 300: 1774–1783.
14. Ligthart S. A., Moll van Charante E. P., Van Gool W. A., Richard E. Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: A systematic review. *Journal of Vascular Health and Risk Management*. 2010; 6: 775–785.
15. Morris M. C., Evans D. A., Schneider J. A., Tangney C. C., Bienias J. L., Aggarwal N. T. Dietary folate and vitamins B-12 and B-6 not associated with incident Alzheimer's disease. *Journal of Alzheimer's Disease*. 2006; 9: 435–443.
16. Bona K. H., Njolstad I., Ueland P.M. et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. *New England Journal of Medicine*. 2006; 354: 1578–1588.

17. Feng L., Li J., Yap K. B., Kua E. H., Ng T. P. Vitamin B-12, apolipoprotein E genotype, and cognitive performance in community-living older adults: Evidence of a gene-micronutrient interaction. *AJCN*. 2009; 89: 1263–68.
18. Morris M. C., Evans D. A., Tangney C. C., Bienias J. L., Wilson R. S. Associations of vegetable and fruit consumption with age-related cognitive change. *Neurology*. 2006; 67: 1370–1376.
19. Dauchet L., Amouyel P., Dallongeville J. Fruit and vegetable consumption and risk of stroke: A meta-analysis of cohort studies. *Neurology*. 2005; 65: 1193–1197.
20. He F. J., Nowson C. A., MacGregor G. A. Fruit and vegetable consumption and stroke: Meta-analysis of cohort studies. *Lancet*. 2006; 367: 320–326.
21. Oude Griep L. M., Monique Verschuren W. M., Kromhout D., Ocke M. C., Geleijnse J. M. Colours of fruit and vegetables and 10-year incidence of CHD. *British Journal of Nutrition*. 2011; 106: 1562–1569.
22. Oude Griep L. M., Verschuren W. M. M., Kromhout D., Ocke M. C., Geleijnse J. M. Colors of fruit and vegetables and 10-year incidence of stroke. *Stroke*. 2011; 42: 3190–3195.
23. Krikorian R., Nash T. A., Shidler M. D., Shukitt-Hale B., Joseph J. A. Concord grape juice supplementation improves memory function in older adults with mild cognitive impairment. *British Journal of Nutrition*. 2010; 103: 730–734.
24. Krikorian R., Shidler M. D., Nash T. A. et al. Blueberry supplementation improves memory in older adults. *Journal of Agricultural and Food Chemistry*. 2010; 58: 3996–4000.
25. Letenneur L. Risk of dementia and alcohol and wine consumption: A review of recent results. *Journal of Biological Research*. 2004; 37: 189–193.
26. Ioannou G. N., Dominitz J. A., Weiss N. S., Heagerty P. J., Kowdley K. V. The effect of alcohol consumption on the prevalence of iron overload, iron deficiency, and iron deficiency anemia. *Gastroenterology*. 2004; 126: 1293–1301.
27. Eskelinen M. H., Kivipelto M. Caffeine as a protective factor in dementia and Alzheimer's disease. *Journal of Alzheimer's Disease*. 2010; 20: S167–S174.

5. kapitola Duševní cvičení budující kognitivní rezervu

1. Rentz D. M., Locascio J. J., Becker J. A. et al. Cognition, reserve, and amyloid deposition in normal aging. *Annals of Neurology*. 2010; 67: 353–364.
2. Yaffe K., Weston A., Graff-Radford N. R. Association of plasma β -amyloid level and cognitive reserve with subsequent cognitive decline. *JAMA*. 2011; 305: 261–266.
3. Wilson R. S., Bennett D. A., Bienias J. L. et al. Cognitive activity and incident AD in a population-based sample of older persons. *Neurology*. 2002; 59: 1910–1914.

4. Willis S. L., Tennstedt S. L., Marsiske M. et al. Long-term effects of cognitive training on everyday functional outcomes in older adults. *JAMA*. 2006; 296: 2805–2814.
5. Jean L., Bergeron M. E., Thivierge S., Simard M. Cognitive intervention programs for individuals with mild cognitive impairment: Systematic review of the literature. *American Journal of Geriatric Psychiatry*. 2010; 18: 281–296.
6. Craik F. I. M., Bialystok E., Freedman M. Delaying the onset of Alzheimer disease: Bilingualism as a form of cognitive reserve. *Neurology*. 2010; 75: 1726–29.
7. Chertkow H., Whitehead V., Phillips N., Wolfwon C., Atherton J., Bergman H. Multilingualism (but not always bilingualism) delays the onset of Alzheimer disease: Evidence from a bilingual community. *Alzheimer Disease Associated Disorders*. 2010; 24: 118–125.
8. Kavé G., Eyal N., Shorek A., Cohen-Mansfield J. Multilingualism and cognitive state in the oldest old. *Psychology and Aging*. 2008; 23; 70–78.
9. Inoue S., Matsuzawa T. Working memory of numerals in chimpanzees. *Current Biology*. 2007; 17(23): R1004– R1005.
10. Inoue S., Matsuzawa T. Acquisition and memory of sequence order in young and adult chimpanzees (*Pan troglodytes*). *Animal Cognition*. 2009; 12, dodatek 1: S59–S69.

6. kapitola Fyzické cvičení k udržení mozku v dobré kondici

1. Pereira A. C., Huddleston D. E., Brickman A. M. et al. An in vivo correlate of exercise-induced neurogenesis in the adult dentate gyrus. *Proc Natl Acad Sci USA*. 2007; 104: 5638–5643.
2. Colcombe S. J., Erickson KI., Scalf P. E. et al. Aerobic exercise training increases brain volume in aging humans. *J. Gerontol A Biol Sci Med Sci*. 2006; 61: 1166–1170.
3. Erickson K. I. , Voss M. W., Prakash R. S. et al. Exercise training increases size of hippocampus and improves memory. *Proc Natl Acad Sci USA*. 2011; 108: 3017–3022.
4. Larson E. B., Wang L., Bowen J. D. et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. *Annals of Internal Medicine*. 2006; 144: 73–81.
5. Scarmeas N., Luchsinger J. A., Schupf N. et al. Physical activity, diet, and risk of Alzheimer disease. *JAMA*. 2009; 302: 627–637.
6. Rovio S., Kareholt I., Helkala E. L. et al. Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. *Lancet Neurology*. 2005; 4: 705–711.

7. Hamer M., Chida Y. Physical activity and risk of neurodegenerative disease: A systematic review of prospective evidence. *Psychological Medicine*. 2009; 39: 3–11.

8. Foster P. P., Rosenblatt K. P., Kuljis R. O. Exercise-induced cognitive plasticity, implications for mild cognitive impairment and Alzheimer's disease. *Frontiers in Neurology*. 2011; 2: 1–15.

9. Voss M. W., Chaddock L., Kim J. S. et al. Aerobic fitness is associated with greater efficiency of the network underlying cognitive control in preadolescent children. *Neuroscience*. 2011; 29; 199: 166–176.

10. Boule N. G., Haddad E., Kenny G. P., Wells G. A., Sigal R. J. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: A meta-analysis of controlled clinical trials. *JAMA*. 2001; 286: 1218–1227.

11. Curioni C. C., Lourenco P. M. Long-term weight loss after diet and exercise: A systematic review. *International Journal of Obesity (Lond)* 2005; 29: 1168–1174.

12. Colcombe S. J., Kramer A. F., Erickson K. I. et al. Cardiovascular fitness, cortical plasticity, and aging. *Proc Natl Acad Sci USA*. 2004; 101: 3316–3321.

7. kapitola Zlepšení kapacity paměti během spánku

1. Wagner U., Born J. Memory consolidation during sleep: Interactive effects of sleep stages and HPA regulation. *Stress*. 2008; 11: 28–41.

2. Huang Y., Potter R., Sigurdson W. et al. Effects of age and amyloid deposition on α dynamics in the human central nervous system. *Archives of Neurology*. 2012; 69: 51–58.

8. kapitola Léky a zdravotní potíže ovlivňující paměť

1. Preiss D., Seshasai S. R., Welsh P. et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. *JAMA*. 2011; 305: 2556–2564.

2. Evans M. A., Golomb B. A. Statin-associated adverse cognitive effects: Survey results from 171 patients. *Pharmacotherapy*. 2009; 29: 800–811.

3. Cherrier M., Amory J., Ersek M., Risler L., Shen D. Comparative cognitive and subjective side effects of immediate release oxycodone in healthy middle age and older adults. *Journal of Pain*. 2009; 10: 1038–1050.

4. Ockene J. K., Barad D. H., Cochrane B. B. et al. Symptom experience after discontinuing use of estrogen plus progestin. *JAMA*. 2005; 294: 183–193.

5. Le Pira F., Zappala G., Giuffrida S. et al. Memory disturbances in migraine with and without aura: A strategy problem? *Cephalalgia*. 2000; 20: 475–478.

6. Farmer K., Cady R., Bleiberg J. et al. Sumatriptan nasal spray and cognitive function during migraine: Results of an open-label study. *Headache*. 2001; 41: 377–384.

7. Brezden C. B., Phillips K. A., Abdolell M., Bunston T., Tannock I. F. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. *Journal of Clinical Oncology*. 2000; 18: 2695–2701.

8. Dietrich J., Han R., Yang Y., Mayer-Proschel M., Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. *Journal of Biology*. 2006; 5: 22.

9. Ohara T., Doi Y., Ninomiya T. et al. Glucose tolerance status and risk of dementia in the community: The Hisayama study. *Neurology*. 2011; 77: 1126–1134.

9. kapitola Strava podporující paměť a myšlení

1. Ornish D., Brown S. E., Scherwitz L. W. et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. *Lancet*. 1990; 336: 129–133.

2. Ornish D., Scherwitz L. W., Billings J. H. et al. Intensive lifestyle changes for reversal of coronary heart disease. *JAMA*. 1998; 280: 2001–2007.

3. Barnard N. D., Scialli A. R., Turner-McGrievy G., Lanou A. J., Glass J. The effects of a low-fat, plant-based dietary intervention on body weight, metabolism, and insulin sensitivity. *American Journal of Medicine*. 2005; 118: 991–997.

4. Barnard N. D., Cohen J., Jenkins D. J. et al. A low-fat, vegan diet improves glycaemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes. *Diabetes Care*. 2006; 29: 1777–1783.

5. Tonstad S., Butler T., Yan R., Fraser G. E. Type of vegetarian diet, body weight and prevalence of type 2 diabetes. *Diabetes Care*. 2009; 32: 791–796.

6. Anderson J. W., Gustafson N. J., Spencer D. B., Tietyen J., Bryant C. A. Serum lipid response of hypercholesterolemic men to single and divided doses of canned beans. *AJCN*. 1990; 51: 1013–1019.

7. Messina M., Messina V. *The Simple Soybean and Your Health*. Avery Publishing Group, Garden City Park, New York, 1994.

8. Mukuddem-Petersen J., Oosthuizen W., Jerling J. C. A systematic review of the effects of nuts on blood lipid profiles in humans. *Journal of Nutrition*. 2005; 135: 2082–2089.

9. Jenkins D. J., Kendall C. W., Marchie A. et al. Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants. *AJCN*. 2005; 81: 380–387.

10. Davis B. C., Kris-Etherton P. Achieving optimal essential fatty acid status in vegetarians: Current knowledge and practical implications. *AJCN*. 2003; 78 (do-datek): 640S–646S.

10. kapitola Jak překonat touhu po jídle

1. David Sheff. Interview with John Lennon and Yoko Ono. *Playboy* [online], leden 1981. [vid. 3. 9. 2011]. Dostupné na: <http://www.beatlesinterviews.org/db1980.jlpb.beatles.html>.
2. Ray Coleman. *The Man Who Made the Beatles: An Intimate Biography of Brian Epstein*. McGraw Hill, New York, 1989, s. 10–15, 318–341.
3. Yeomans M. R., Wright P., Macleod H. A., Critchley J. A. J. H. Effects of nalmefene on feeding in humans. *Psychopharmacology*. 1990; 100: 426–432.
4. Barnard N. D., Noble E. P., Ritchie T. et al. D2 Dopamine receptor Taq1A polymorphism, body weight, and dietary intake in type 2 diabetes. *Nutrition*. 2009; 25: 58–65.
5. The Vegetarian [online] February 1992 [vid. 6. 11. 2011]. Dostupné na: <http://www.eatveg.com/paul.htm>.

1. dodatek Léky a potravinové doplňky na poruchy paměti

1. Schneider L. S., Dagerman K. S., Higgins J. P., McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. *Archives of Neurology*. 2011; 68: 991–998.
2. Craft S., Baker L. D., Montine T. J. et al. Intranasal insulin therapy for Alzheimer disease and amnesic mild cognitive impairment. *Archives of Neurology*. 2012; 69: 29–38.
3. Barnard N. D., Cohen J., Jenkins D. J. et al. A low-fat, vegan diet improves glycaemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes. *Diabetes Care*. 2006; 29: 1777–1783.
4. Barnard N. D., Cohen J., Jenkins D. J. et al. A low-fat vegan diet and a conventional diabetes diet in the treatment of type 2 diabetes: A randomized, controlled, 74-week clinical trial. *AJCN*. 2009; 89 (dodatek): 1588S–1596S.
5. Barnard N. D., Scialli A. R., Turner-McGrievy G., Lanou A. J., Glass J. The effects of a low-fat, plant-based dietary intervention on body weight, metabolism, and insulin sensitivity. *American Journal of Medicine*. 2005; 118: 991–997.
6. Nicoll J. A. R., Wilkinson D., Holmes C., Steart P., Markham H., Weller R. O. Neuropathology of human Alzheimer disease after immunization with amyloid- β peptide: A case report. *Nature Medicine*. 2003; 9: 448–452.
7. Ostrowitzki S., Deptula D., Thurfjell L. et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. *Archives of Neurology*, 10. 10. 2011.

8. Badiola N., Suárez-Calvet M., Lleó A. Tau phosphorylation and aggregation as a therapeutic target in tauopathies. *CNS & Neurological Disorders—Drug Targets*. 2010; 9: 727–740.
9. Kanowski S., Hoerr R. Ginkgo biloba extract EGb 761 in dementia: Intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. *Pharmacopsychiatry*. 2003; 36: 297–303.
10. DeKosky S. T., Williamson J. D., Fitzpatrick A. L. et al. Ginkgo biloba for prevention of dementia: A randomized controlled trial. *JAMA*. 2008; 300: 2253–2262.
11. Snitz B. E., O’Meara E. S., Carlson M. C. et al. Ginkgo biloba for preventing cognitive decline in older adults: A randomized trial. *JAMA*. 2009; 302: 2663–2670.
12. Birks J., Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. *Cochrane Database of Systematic Reviews*. 2009; 21: CD003120.
13. Kato-Kataoka A., Sakai M., Ebina R., Nonaka C., Asano T., Miyamori T. Soybean-derived phosphatidylserine improves memory function of the elderly Japanese subjects with memory complaints. *Journal of Clinical Biochemistry and Nutrition*. 2010; 47: 246–255.
14. Richter Y., Herzog Y., Cohen T., Steinhart Y. The effect of phosphatidylserine-containing omega-3 fatty acids on memory abilities in subjects with subjective memory complaints: A pilot study. *Journal of Clinical Interventions in Aging*. 2010; 5: 313–316.
15. Jorissen B. L., Brouns F., Van Boxtel M. P. et al. The influence of soy-derived phosphatidylserine on cognition in age-associated memory impairment. *Nutritional Neuroscience*. 2001; 4: 121–134.